These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
1693 related items for PubMed ID: 17717597
21. The proteolytic activity of separase in BCR-ABL-positive cells is increased by imatinib. Haaß W, Stehle M, Nittka S, Giehl M, Schrotz-King P, Fabarius A, Hofmann WK, Seifarth W. PLoS One; 2012; 7(8):e42863. PubMed ID: 22870341 [Abstract] [Full Text] [Related]
22. A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9. Dash AB, Williams IR, Kutok JL, Tomasson MH, Anastasiadou E, Lindahl K, Li S, Van Etten RA, Borrow J, Housman D, Druker B, Gilliland DG. Proc Natl Acad Sci U S A; 2002 May 28; 99(11):7622-7. PubMed ID: 12032333 [Abstract] [Full Text] [Related]
23. A novel HDAC inhibitor chidamide combined with imatinib synergistically targets tyrosine kinase inhibitor resistant chronic myeloid leukemia cells. He B, Wang Q, Liu X, Lu Z, Han J, Pan C, Carter BZ, Liu Q, Xu N, Zhou H. Biomed Pharmacother; 2020 Sep 28; 129():110390. PubMed ID: 32563150 [Abstract] [Full Text] [Related]
24. Imatinib resistance associated with BCR-ABL upregulation is dependent on HIF-1alpha-induced metabolic reprograming. Zhao F, Mancuso A, Bui TV, Tong X, Gruber JJ, Swider CR, Sanchez PV, Lum JJ, Sayed N, Melo JV, Perl AE, Carroll M, Tuttle SW, Thompson CB. Oncogene; 2010 May 20; 29(20):2962-72. PubMed ID: 20228846 [Abstract] [Full Text] [Related]
25. Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells. Mak DH, Schober WD, Chen W, Konopleva M, Cortes J, Kantarjian HM, Andreeff M, Carter BZ. Mol Cancer Ther; 2009 Sep 20; 8(9):2509-16. PubMed ID: 19723894 [Abstract] [Full Text] [Related]
26. PECAM-1 is involved in BCR/ABL signaling and may downregulate imatinib-induced apoptosis of Philadelphia chromosome-positive leukemia cells. Wu N, Kurosu T, Oshikawa G, Nagao T, Miura O. Int J Oncol; 2013 Feb 20; 42(2):419-28. PubMed ID: 23233201 [Abstract] [Full Text] [Related]
30. AID expression is correlated with Bcr-Abl expression in CML-LBC and can be down-regulated by As2O3 and/or imatinib. Liu Z, Wu X, Duan Y, Wang Y, Shan B, Kong J, Ma X, Bao Y. Leuk Res; 2011 Oct 20; 35(10):1355-9. PubMed ID: 21570118 [Abstract] [Full Text] [Related]
31. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Cortes J, Rousselot P, Kim DW, Ritchie E, Hamerschlak N, Coutre S, Hochhaus A, Guilhot F, Saglio G, Apperley J, Ottmann O, Shah N, Erben P, Branford S, Agarwal P, Gollerkeri A, Baccarani M. Blood; 2007 Apr 15; 109(8):3207-13. PubMed ID: 17185463 [Abstract] [Full Text] [Related]
36. Sphingosine kinase-1 and sphingosine 1-phosphate receptor 2 mediate Bcr-Abl1 stability and drug resistance by modulation of protein phosphatase 2A. Salas A, Ponnusamy S, Senkal CE, Meyers-Needham M, Selvam SP, Saddoughi SA, Apohan E, Sentelle RD, Smith C, Gault CR, Obeid LM, El-Shewy HM, Oaks J, Santhanam R, Marcucci G, Baran Y, Mahajan S, Fernandes D, Stuart R, Perrotti D, Ogretmen B. Blood; 2011 Jun 02; 117(22):5941-52. PubMed ID: 21527515 [Abstract] [Full Text] [Related]
37. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. George P, Bali P, Annavarapu S, Scuto A, Fiskus W, Guo F, Sigua C, Sondarva G, Moscinski L, Atadja P, Bhalla K. Blood; 2005 Feb 15; 105(4):1768-76. PubMed ID: 15514006 [Abstract] [Full Text] [Related]
38. [Efficacy of dasatinib in treatment of imatinib-resistant BCR/ABL positive leukemia]. Zhu Y, Pan LQ, Qian SX, Song P, Yu H, Zhang SJ, Ge Z, Hong M, Tian T, Li JY. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun 15; 21(3):581-6. PubMed ID: 23815902 [Abstract] [Full Text] [Related]
39. Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin. Nimmanapalli R, O'Bryan E, Huang M, Bali P, Burnette PK, Loughran T, Tepperberg J, Jove R, Bhalla K. Cancer Res; 2002 Oct 15; 62(20):5761-9. PubMed ID: 12384536 [Abstract] [Full Text] [Related]
40. Establishment of a new Glivec-resistant chronic myeloid leukemia cell line, SNUCML-02, using an in vivo model. Park J, Kim KI, Koh Y, Won NH, Oh JM, Lee DS, Kim BK, Ahn KS, Yoon SS. Exp Hematol; 2010 Sep 15; 38(9):773-81. PubMed ID: 20438801 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]